Effect of Statins Therapy in Diabetogenesis
DOI:
https://doi.org/10.17140/TFMOJ-5-130Keywords:
type II diabetes (DM), cardiovascular disease (CVD), β-hydroxy β-methyl glutaryl-CoA (HMG-CoA), level of low-density lipoproteins (LDL), glucose transporter (GLUT 4)Abstract
Statins are widely used in the management or inhibition of several processes that lead to the development of cardiovascular diseases. Increased statin therapy has been related to the induction of type II diabetes (DM), a state which predisposes to cardiovascular disease (CVD). Statins are well-known to possess anti-inflammatory properties and the ability to disrupt de novo bio synthesis of cholesterol and lipid homeostasis has been implicated in the induction of inflammatory responses within pancreatic β-cells. Inhibition of β-hydroxy β-methyl glutaryl-CoA (HMG-CoA) results an increased level of low-density lipoproteins (LDL) receptors. Increased LDL receptor numbers will replenish exhausted intracellular supplies, resulting in higher levels of intracellular cholesterol. Therefore, stimulating immunological response and inflammatory reactions, disrupt the functional integrity of the β-cell via oxidation of the plasma-derived low-density lipoprotein. Despite the pleiotropic effects of statins on the pancreatic β-cell, they have also been reported to affect a number of other cell types associated with the development of diabetes. Inhibition of the biosynthesis of isoprenoid by statins has been associated with the down-stream regulation of glucose transporter (GLUT 4) in adipose tissues, which facilitates the uptake of glucose. This effect resulted in increasing resistance to insulin in the liver, muscle, and adipose tissue. Adiponectin, a plasma protein released by adipocytes, alters fatty acids and carbohydrate metabolism both in the muscle cells and liver. This process indirectly influences resistance to insulin by the attendant decrease in hepatic gluconeogenesis and to upregulate muscular β-oxidation and glucose uptake.
References
Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepav-ich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the women’s health initia-tive. Arch Intern Med. 2012; 172(2): 144-152. doi: 10.1001/archin-ternmed.2011.625
SHARP Collaborative Group. Study of heart and renal protec-tion (SHARP): Randomized trial to assess the effects of lower-ing low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010; 160(5): 785-794.e10. doi: 10.1016/j.ahj.2010.08.012
Cederberg H, Stancakova A, Yaluri N, Modi S, Kuusisto J, Laak-so M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: A 6-year follow-up study of the METSIM cohort. Diabetologia. 2015; 58(5): 1109-1117. doi: 10.1007/s00125-015-3528-5
Arnaud C, Veillard NR, Mach F. Cholesterol-independent ef-Mini Review | Volume 5 | Number 1| Olagunju AS et al fects of statins inInflammation, immuno-modulation and athero-sclerosis. Curr Drug Targets Cardiovasc Haematol Disord. 2005; 5(2): 127-134. doi: 10.2174/1568006043586198
Moghadasian MH. Clinical pharmacology of 3-hydroxy-3-meth-ylglutaryl coenzyme a reductase inhibitor. Life Sci. 1999; 65: 1329- 1337. doi: 10.1016/s0024-3205(99)00199-x
Unoki H, Takahashi A, Kawaguchi T, Hara K, Horikoshi M, An-dersen G, et al. SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet. 2008; 40(9): 1098-1102. doi: 10.1038/ng.208
Mabuchi H, Higashikata T, Kawashiri M, Katsuda S, Mizuno M, Nohara A, et al. Reduction of serum ubiquinol-10 and ubiqui-none-10 levels by atorvastatin in hypercholesterolemic patients. J Atherosclerosis Thromb.. 2005; 12(2): 111-119. doi: 10.5551/jat.12.111
Salunkhe VA, Elvstam O, Eliasson L, Wendt A. Rosuvastatin treatment affects both basal and glucose-induced insulin secre-tion in INS-1832/13 Cells. PLoS One. 2016; 11(3): e0151592. doi: 10.1371/journal.pone.0151592
Aiman U, Najmi A, Khan RA. Statin induced diabetes and its clinical implications. J Pharmacol Pharmacotherapy. 2014; 5(3): 181185. doi: 10.4103/0976-500X.136097
Supale S, Li N, Brun T, Maechler P. Mitochondrial dysfunction in pancreatic β cells. Trends Endocrinol Metab. 2012; 23(9): 477487. doi: 10.1016/j.tem.2012.06.002
Wang C-H, Wang C-C, Huang H-C, Wei Y-H. Mitochondrial dysfunction leads to impairment ofinsulin sensitivity and adipo-nectin secretionin adipocytes. FEBS J. 2013; 280(4): 1039-1050. doi: 10.1111/febs.12096
Phielix E, Mensink M. Type 2 diabetes mellitus and skeletal muscle metabolic function. Physiol Behav. 2008; 94(2): 252-258. doi: 10.1016/j.physbeh.2008.01.020
Preiss D, Seshasai SRK, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dosecompared with moderate-dose statin therapy: ameta-analysis. JAMA. 2011; 305(24): 2556-2564. doi: 10.1001/jama.2011.860
Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on theadipocyte maturation and expres-sion of glucose transporter 4(SLC2A4): Implications in glycaemic control. Diabetologia. 2006; 49(8): 1881-1892. doi: 10.1007/s00125- 006-0269-5
Manzoni M, Rollini M. Biosynthesis and biotechnological pro-duction of statins by filamentous fungi and application of these cholesterol-lowering drugs. Appl Microbiol Biotechnol. 2002; 58: 555- 564. doi: 10.1007/s00253-002-0932-9
Schachter M. Chemical, pharmacokinetic and pharmacody-namic properties of statins: An update. Fundam Clin Pharmacol. 2005; 19: 117-125. doi: 10.1111/j.1472-8206.2004.00299.x
Shepherd J. Who should receive a statin these days? Lessons from recent clinical trials. J Intern Med. 2006; 260: 305-309. doi: 10.1111/j.1365-2796.2006.01700.x
Sirvent P, Mercier J, Vassort G, Lacampagne A. Simvastatin triggers mitochondriainduced Ca2+signalling alteration in skeletal muscle. Biochem Biophys Res Commun. 2005; 329: 1067-1075. doi: 10.1016/j.bbrc.2005.02.070
Demyanets S, Kaun C, Pfaffenberger S, Hohensinner PJ, Rega G, Pammer J. Hydroxymethylglutaryl-coenzyme a reductase inhibi-tors induce apoptosis in human cardiac myocytes in vitro. Biochem Submit your article to this journal | https://openventio.org/submit-manuscript/ 4 Olagunju AS et al Pharmacol. 2006; 71: 1324-1330. doi: 10.1016/j.bcp.2006.01.016
Sacher J, Weigl L, Werner M, Szegedi C, Hohenegger M. Delin-eation of myotoxicity induced by 3-hydroxy-3 methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. J Pharmac Exp Ther. 2005; 314: 1032-1041. doi: 10.1124/jpet.105.086462
Cafforio P, Dammacco F, Gernone A, Silvestris F. Statins ac-tivate the mitochondrial pathway of apoptosis in human lympho-blasts and myeloma cells. Carcinogenesis. 2005; 26: 883-891. doi: 10.1093/carcin/bgi036
Paul DT, Gregory P, Amanda Z, Beth T. Statin-associated side effects. J Am Coll Cardiol. 2016; 67(20): 2395-2410. doi: 10.1016/j. jacc.2016.02.071 Mini Review | Volume 5 | Number 1|
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Toxicology and Forensic Medicine (TFM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
